I agree that this site is using cookies. You can find further informations here.
X
Jasper Dingemanse
325  results:
Search for persons X
?
1

Parkinson's Disease Symptom Inventory (PDSI): A Comprehensi..:

Thomas J. Hogan ; Roberto Grimaldi ; Jasper Dingemanse...
Quality of Life Research.  7 (1998)  7 - p. 607-608 , 1998
Link: https://www.jstor.org/st..
 
?
2

Quantification of increased biologically active CXCL12α pla..:

Blattmann, Peter ; Farine, Hervé ; Dan, Brian...
Clinical and Translational Science.  17 (2024)  2 - p. , 2024
Link: https://doi.org/10.1111/..
 
?
3

Transfer of the Dual Orexin Receptor Antagonist Daridorexan..:

Kaufmann, Priska ; Muehlan, Clemens ; Anliker‐Ort, Marion...
The Journal of Clinical Pharmacology.  , 2024
Link: https://doi.org/10.1002/..
 
?
4

0169 Nighttime Safety of Daridorexant: Response to Noise St..:

Muehlan, Clemens ; Koopmans, Ingrid ; Magliocca, Massimo...
SLEEP.  47 (2024)  Supplement_1 - p. A73-A73 , 2024
Link: https://doi.org/10.1093/..
 
?
5

Population pharmacokinetics of the dual endothelin receptor..:

Brussee, Janneke M. ; Sidharta, Patricia N. ; Dingemanse, Jasper.
Journal of Pharmacokinetics and Pharmacodynamics.  51 (2024)  3 - p. 243-252 , 2024
Link: https://doi.org/10.1007/..
 
?
6

Effect of Daridorexant on the Pharmacokinetics of Midazolam..:

Zenklusen, Isabelle ; Dingemanse, Jasper ; Reh, Christian..
Drugs in R&D.  24 (2024)  1 - p. 97-108 , 2024
Link: https://doi.org/10.1007/..
 
?
7

Value of Assessing 1‐Hydroxymidazolam in Drug‐Drug Interact..:

Magliocca, Massimo ; Berger, Benjamin ; Lemoine, Vincent..
The Journal of Clinical Pharmacology.  , 2024
Link: https://doi.org/10.1002/..
 
?
8

0100 Excretion of the Dual Orexin Receptor Antagonist Darid..:

Kaufmann, Priska ; Anliker-Ort, Marion ; Siebers, Nicholas..
SLEEP.  47 (2024)  Supplement_1 - p. A44-A44 , 2024
Link: https://doi.org/10.1093/..
 
?
9

Effect of Daridorexant on the Pharmacokinetics of P-Glycopr..:

Anliker-Ort, Marion ; Dingemanse, Jasper ; Janů, Luboš.
Clinical Drug Investigation.  43 (2023)  11 - p. 827-837 , 2023
Link: https://doi.org/10.1007/..
 
?
10

Evaluation of the cytochrome P450 2C19 and 3A4 inhibition p..:

Anliker‐Ort, Marion ; Dingemanse, Jasper ; Delahaye, Stephane...
Clinical and Translational Science.  16 (2023)  7 - p. 1220-1231 , 2023
Link: https://doi.org/10.1111/..
 
?
11

Clinical pharmacology of selatogrel for self-administration..:

Gehin, Martine ; Storey, Robert F. ; Bernaud, Corine.
Expert Opinion on Drug Metabolism & Toxicology.  19 (2023)  10 - p. 697-708 , 2023
Link: https://doi.org/10.1080/..
 
?
12

Modeling time‐delayed concentration‐QT effects with ACT‐101..:

Anliker‐Ort, Marion ; Hsin, Chih‐hsuan ; Krause, Andreas...
Pharmacology Research & Perspectives.  11 (2023)  4 - p. , 2023
Link: https://doi.org/10.1002/..
 
?
13

Pharmacokinetics, pharmacodynamics and safety of the novel ..:

Boof, Marie‐Laure ; Géhin, Martine ; Voors‐Pette, Christine...
British Journal of Clinical Pharmacology.  90 (2023)  2 - p. 588-599 , 2023
Link: https://doi.org/10.1111/..
 
?
14

Effect of nivasorexant (ACT‐539313), a selective orexin‐1‐r..:

Berger, Benjamin ; Kaufmann, Priska ; Berse, Matthias...
Pharmacology Research & Perspectives.  11 (2023)  5 - p. , 2023
Link: https://doi.org/10.1002/..
 
?
15

Mind the Gap: Model-Based Switching from Selatogrel to Main..:

Hsin, Chih-hsuan ; Dingemanse, Jasper ; Henrich, Andrea...
Biomolecules.  13 (2023)  9 - p. 1365 , 2023
Link: https://doi.org/10.3390/..
 
1-15